9th Oct 2008 07:00
Embargoed for 7am Thursday 9th October 2008
ReGen Therapeutics Plc
First launch of ColostrininTM in European Union by Golgi Pharmaceuticals Ltd in the Republic of Cyprus.
ReGen Therapeutics Plc ('ReGen') announces that Development Director Tim Shilton made a presentation, in the Republic of Cyprus on the evening of 8th October 2008, to a number of neurology specialists as part of the official launch of ColostrininTM, as CognaseTM, in Cyprus. Mr Shilton gave a detailed appraisal of CognaseTM and a copy of his presentation can be found on the ReGen website: www.regentherapeutics.com. The launch was sponsored by Golgi Pharmaceuticals Ltd ("Golgi"), the first European Union distributor of ColostrininTM. Information on CognaseTM, as provided by Golgi, can be viewed at the following website: www.healthybrainaging.com
Commenting on the first launch of ColostrininTM in the European Union, Percy Lomax, Chairman and Chief Executive Officer of ReGen said:
'The launch of CognaseTM into the professional and retail channels in Cyprus allows distribution in all health food stores and pharmacies. We have high hopes that the enthusiasm for the product that we have already seen elsewhere in the world will continue into this new area of distribution and we wish everyone at Golgi the very best of luck for the future.'
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396
David Scott/Nick Bealer
Alexander David
Tel: 020 7448 9820
Adrian Duffield/Jon Davies
College Hill Associates
Tel: 020 7457 2020
Related Shares:
TILS.L